GeneLink Inc. Restates Unaudited Earnings Results for the Three Months Ended March 31, 2011, Second Quarter and Six Months Ended June 30, 2011 and Third Quarter and Nine Months Ended September 30, 2011
May 12, 2012 at 02:58 am IST
Share
GeneLink Inc. restated unaudited earnings results for the three months ended March 31, 2011, second quarter and six months ended June 30, 2011 and third quarter and nine months ended September 30, 2011. For the three months, operating loss restated amounts to $487,380 against reported amount of $444,642; net loss restated is $592,496 against reported amount of $568,459.
For the second quarter ended June 30, 2011, operating loss restated amounts to $813,373 against reported amount of $772,832; net loss restated amounts to $826,416 against net loss reported amount of $801,533.
For the six months ended June 30, 2011, operating loss restated amounts to $1,294,160 against reported amount of $1,210,881; net loss restated amounts to $1,418,912 against net loss reported amount of $1,369,992.
For the third quarter ended September 30, 2011, operating loss restated amounts to $916,838 against reported amount of $880,009; net loss restated amounts to $978,267 against net loss reported amount of $954,230.
For the nine months ended September 30, 2011, operating loss restated amounts to $2,261,000 against reported amount of $2,140,892; net loss restated amounts to $2,163,847 against net loss reported amount of $2,090,890.
Genelink, Inc. is a supplier of custom oligonucleotides. The Company offers a range of commercially available modifications, fluorescently labeled probes, and specialized probes, such as Molecular Beacons, TaqMan, and Fluorescence resonance energy transfer (FRET), as well as a variety of other molecular biology products, such as linkers, adaptors, deoxyribonucleic acid (DNA) purification and clean-up kits. The Companyâs product line of gene detection systems comprises reagents and reagent systems for scientists in the detection of genetic disorders. The Company focuses on triple repeat disorders, which include fragile x, myotonic dystrophy, huntington's disease. It also specializes in the synthesis of ribonucleic acid (RNA) modified oligos, RNA fluorescent probes with quenchers, chimeric oligos containing various combinations of DNA, 2'O methyl bases and phosphorothioate linkages. It serves various industries, including research institutes, pharmaceutical companies and hospitals.
GeneLink Inc. Restates Unaudited Earnings Results for the Three Months Ended March 31, 2011, Second Quarter and Six Months Ended June 30, 2011 and Third Quarter and Nine Months Ended September 30, 2011